Anixa Biosciences Inc
ANIX Nasdaq
SEC CIK 715446
Follow Anixa Biosciences
Weekly email: filings, results
Net income
−$2.6M
−15.4% vs same quarter last year
EPS, diluted
−$0.08
−14.3% vs same quarter last year
Operating cash flow
−$1.8M
−17.1% vs same quarter last year
Operating income
−$2.7M
−12.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$10.9M |
| FY24 | $210K | −$12.6M |
| FY23 | $210K | −$9.8M |
| FY22 | - | - |
| FY21 | $512K | −$13M |
| FY20 | - | −$10M |
| FY19 | $250K | −$11.6M |
| FY18 | $1.1M | −$14M |
| FY17 | $362.5K | −$5M |
| FY16 | $300K | −$5M |
| FY15 | $9.3M | −$1.4M |
| FY14 | $3.7M | −$9.6M |
| FY13 | $388.9K | −$10.1M |
| FY12 | $940K | −$4.3M |
| FY11 | $1M | −$7.4M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | −6586.2% | −5978.1% |
| FY23 | −5243.3% | −4671.9% |
| FY22 | - | - |
| FY21 | −2565.6% | −2530.1% |
| FY20 | - | - |
| FY19 | −4756% | −4658.8% |
| FY18 | −1284.4% | −1258.1% |
| FY17 | −1676% | −1381.8% |
| FY16 | −1503% | −1672.1% |
| FY15 | −10.2% | −14.9% |
| FY14 | −137.5% | −261.9% |
| FY13 | −2036.2% | −2592.3% |
| FY12 | −439.8% | −452.4% |
| FY11 | −501.2% | −735.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | −$6.2M |
| FY19 | −$4.9M |
| FY18 | −$4.3M |
| FY17 | −$3.8M |
| FY16 | −$3.5M |
| FY15 | $1.3M |
| FY14 | −$2.4M |
| FY13 | - |
| FY12 | −$3.1M |
| FY11 | −$725K |
- Anixa Biosciences
- Healthcare median
Show the numbers
| Year | Anixa Biosciences | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | −5978.1% | −47% |
| FY23 | −4671.9% | −58% |
| FY22 | - | −80.4% |
| FY21 | −2530.1% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | −4658.8% | −46.2% |
| FY18 | −1258.1% | −49.6% |
| FY17 | −1381.8% | −45.9% |
| FY16 | −1672.1% | −36% |
| FY15 | −14.9% | −37.8% |
| FY14 | −261.9% | −35.5% |
| FY13 | −2592.3% | −37.1% |
| FY12 | −452.4% | −29.1% |
| FY11 | −735.5% | −27.9% |